Advances in Research on the Effects and Mechanisms of Chemokines and Their Receptors in Cancer

Jing Xu1,2†, Jing-quan Li3†, Qi-lei Chen4†, Elena A. Shestakova5, Vsevolod A. Misyurin5, Vadim S. Pokrovsky5,6, Elena M. Tchevkina5, Hu-biao Chen4*, Hang Song2* and Jian-ye Zhang1*

1Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China, 2Department of Biochemistry and Molecular Biology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China, 3The First Affiliated Hospital, Hainan Medical University, Haikou, China, 4School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China, 5N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Moscow, Russia, 6Department of Biochemistry, People’s Friendship University, Moscow, Russia

Cancer is a common and intractable disease that seriously affects quality of life of patients and imposes heavy economic burden on families and the entire society. Current medications and intervention strategies for cancer have respective shortcomings. In recent years, it has been increasingly spotlighted that chemokines and their receptors play vital roles in the pathophysiology of cancer. Chemokines are a class of structurally similar short-chain secreted proteins that initiate intracellular signaling pathways through the activation of corresponding G protein-coupled receptors and participate in physiological and pathological processes such as cell migration and proliferation. Studies have shown that chemokines and their receptors have close relationships with cancer epigenetic regulation, growth, progression, invasion, metastasis, and angiogenesis. Chemokines and their receptors may also serve as potential targets for cancer treatment. We herein summarize recent research progresses on anti-tumor effects and mechanisms of chemokines and their receptors, suggesting avenues for future studies. Perspectives for upcoming explorations, such as development of multi-targeted chemokine-based anti-tumor drugs, are also discussed in the present review.

Keywords: chemokine, chemokine receptor, epigenetic regulation, molecular mechanisms, combination medication

INTRODUCTION

According to the latest statistics from American Cancer Society, the number of cancer cases and deaths remains high throughout the years, and has been even elevated due to delayed diagnosis under the COVID-19 pandemic (Siegel et al., 2022). The whirlwind growth of economy and technology have driven major development of the research on cancer, especially on the pathogenic mechanisms and relevant therapeutic strategies. Among the research topic on cancer, the study of tumor microenvironment stands out due to its close relation to the occurrence, growth, and metastasis of cancer. Tumor microenvironment not only affect the tumor cells themselves, but also the surrounding cells (fibroblasts, immune and inflammatory cells, and glial cells), as well as the interstitial cells, microvasculature, and biomolecules that penetrating into nearby tissues (Hinshaw...
and Shevde 2019; Anderson and Simon 2020; DeBerardinis 2020). Recent studies have shown that the chemokine family is considered closely related to tumor microenvironment. Chemokines are a subfamily of small-molecule cytokines secreted by cells and play an essential role in transportation of immune cells and development of lymphoid tissue, with the function of inducing targeted chemotaxis of neighboring responding cells (van der Vorst et al., 2015; Hughes and Nibbs 2018). To date, 48 different chemokines have been reported, and they can be classified into four classes (C, CC, CXC and CX3C) depending on the number and location of their amino-terminal (N-terminal) pre-cysteines. They exert the biological function through selective binding to their receptors, which are G protein-coupled receptors (GPCRs) expressed on various chemotactic immune cells in tissues, organs, and circulatory system (Miller and Mayo 2017). Recent studies have shown that chemokines and their receptors also serve an important purpose in the induction of immune cells against tumors (Chow and Luster 2014; Nagarsheth et al., 2017). Based on this, the present review focuses on the study of the anti-tumor activity and mechanisms of anti-cancer effect of chemokines, with the aim of providing reference for future research.

STRUCTURE AND FUNCTION OF CHEMOKINES

Chemokines can be classified into 4 classes in accordance to the number and location of their N-terminal pre-cysteines, namely class C, CC, CXC and CX3C (Miller and Mayo 2017) (Figure 1). Their biological effects are exerted through their specific interactions with chemokine receptors (Baggiolini 2001). Chemokine receptors are a kind of GPCRs that are selectively located in the membranes of target cells. To date, approximately 19 different chemokine receptors have been identified, which are also divided into four families based on the chemokine types they bind: CXCR, which binds to CXC chemokines; CCR, which binds to CC chemokines; CX3CR1, which binds to chemokine CX3CL1; and XCR1, which binds to chemokines XCL1 and XCL2 (Sharma 2010; Singh et al., 2011). Detailed chemical classifications are shown in Table 1.

All chemokines are small proteins that are composed of 70–100 amino acids with molecular weights of 8–10 kDa, and have four site-conserved cysteine residues to ensure their tertiary structure (Fernandez and Lolis 2002; Zlotnik and Yoshie 2012). The major function of chemokines is to induce directed migration of target cells, which can be attracted to specific tissues with increased chemokine concentration. In particular, chemokines can mediate leukocyte migration to respective locations during inflammation and homeostasis in vivo (Baggiolini 1998; Thelen and Stein 2008; Borroni et al., 2018). In this way, new light has been shed on antitumor therapy. For example, the CC-like chemokine CCL19 expressed in T cells of secondary lymphoid tissues and organs such as spleen and lymph nodes, is chemotactic to naive T cells and mature DC cells. Its specific receptor is CCR7, which is expressed not only on mature DC cells, macrophages and T cells (Forster et al., 2008; Comerford et al., 2013), but also in many tumor cells, such as colorectal (Xu et al., 2018), lung (Zhang et al., 2017), breast (Muller et al., 2001), and ovarian (Cheng et al., 2014). It has been shown that the interplay between the chemokine and its receptor could inhibit tumor proliferation, migration and invasion (Peng et al., 2015a; Xu et al., 2017; Zhou et al., 2020).

ANTI-TUMOR EFFECT OF CHEMOKINES

Involvement in Epigenetic Regulation

Epigenetics refers to heritable changes in the function of genes without alterations in their DNA sequences, ultimately leading to
variation in the phenotype (Sapienza and Issa 2016). It is generally recognized that cancer epigenetics include modification of DNA and histones, regulation of non-coding RNA, chromatin remodeling, and nucleosome positioning (Dawson and Kouzarides 2012; Toh et al., 2017). Among the above-mentioned forms, methylation of DNA is the most well-studied epigenetic modification (Skvortsova et al., 2019). DNA methylation is a key epigenetic mechanism controlling gene expression, and in general, it inhibits gene transcription by shifting chromatin from a loose state, permissive for the active transcription, to a condensed state that prohibits the transcription (Moore et al., 2013; Zhang et al., 2014). The methylation pattern of DNA in the genome is catalyzed by DNA methyltransferases, which mainly involve DNMT1, DNMT3a, and DNMT3b. Among them, DNMT1 is the methyltransferase that plays a maintenance role, while DNMT3a and DNMT3b are mainly responsible for de novo methylation but also play a role in maintaining methylation (Bestor and Verdine 1994; Tajima et al., 2016).

It was shown that DNMT1-mediated DNA methylation and EZH2-mediated H3K27me3, in the enhancer region, suppressed CCL2 expression in SCLC cells, thereby enhancing tumor progression (Zheng et al., 2021). In addition, CXCL12 was down-regulated in gastric cancer tissues, accompanied by hypermethylation, and the reduced CXCL12 expression was closely associated with lymph node metastasis and histological grading, presumably playing a possible part in gastric cancer cell metastasis (Zhi et al., 2012). Similarly, upregulation of CXCR4 and downregulation of CXCL12 were observed in primary breast cancers. The hypermethylation in the CXCL12 promoter region in more than 50% of breast tumors was detected by methylation-specific PCR, and the expressions of DNMT1 and DNMT3b were distinctly higher in CXCL12-methylated breast cancers than in CXCL12-unmethylated breast cancers (Zhou et al., 2009). Additionally, studies by Ramos et al. and Dayer et al. corroborated the proposed direction that the DNA methylation status of CXCR4 and CXCL12 genes could be used as biomarkers for breast cancer prognosis (Ramos et al., 2011; Dayer et al., 2018). The experiments of Peng et al. showed that EZH2-mediated H3K27me3 and DNMT1-mediated DNA methylation suppressed tumors and produced T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, which could partially alter methylation suppressed tumors and produced T helper 1 (TH1)-mediated H3K27me3 and DNMT1-mediated DNA methylation suppressed tumors and produced T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, which could partially alter methylation suppressed tumors and produced T helper 1 (TH1)-mediated DNA methylation suppressed tumors and produced T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, which could partially alter methylation suppressed tumors and produced T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, which could partially alter methylation suppressed tumors and produced T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, which could partially alter methylation suppressed tumors and produced T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, which could partially alter methylation suppressed tumors and produced T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, which could partially alter methylation suppressed tumors and produced T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, which could partially alter met}

**Table 1** Classification of chemokines.

| Classification       | Chemokines           | Chemokine Receptors | Reference         |
|----------------------|----------------------|---------------------|-------------------|
| CC Chemokines        | CCL1–CCL28            | CCR                 | Singh et al. (2011) |
| CX Chemokines        | CXCL1–CXCL17          | CXCR                | Singh et al. (2011) |
| XC Chemokines        | XCL1, XCL2            | XCR1                | Singh et al. (2011) |
| CX3C Chemokines      | CXCL1                | CX3CR1              | Sharma (2010), Singh et al. (2011) |

Involvement in Tumor Growth and Progression

Numerous experimental studies have established that chemokine signaling systems are involved in tumor growth and development via different mechanisms. For instance, interactions of chemokines with their receptors can directly activate signaling pathways, such as JAK/STAT and PI3K/AKT pathways, leading to cancer progression. More involved chemokines and their receptors acting on cancer are listed in Table 2.

The JAK/STAT pathway is the main signal transduction mechanism of various cytokines and growth factors, and has an important role in the regulation of biological processes such as cell growth, differentiation, proliferation, migration, and apoptosis. Studies have shown that multiple chemokines exert biological effects through JAK/STAT signaling pathway. It was found that CXCL1 was a direct target of miR-302e on cell proliferation, migration, invasion, and apoptosis in colorectal cancer, and the mechanism was correlated with CXCL1 expression regulated by miR-302e and the inactivation of the JAK-STAT signaling pathway (Chen et al., 2020). CXCR1, a receptor for CXCL1, is thought to be significantly related to poor prognosis in patients with NSCLC, and its high expression is mainly involved in signaling pathways such as JAK/STAT. Yang et al. used qRT-PCR and western blot experiments to show that overexpression of CXCR1 enhanced STAT5A expression, while knockdown of CXCR1 inhibited STAT5A expression (Yang et al., 2021). In addition, the combination of FKN and CX3CR1 could also activate the JAK/STAT signaling pathway and promote pancreatic cancer cell proliferation and migration (Huang et al., 2017). Meanwhile, chemokines can
cause an imbalance between pro- and anti-apoptotic proteins in tumor cells. For example, chemokines down-regulated the expression of Bcl-2 and inhibited the activation of caspase-3 and caspase-9, thereby maintaining cancer cell survival and suppressing tumor cell apoptosis (Pang et al., 2015).

The PI3K/AKT pathway is an intracellular signaling pathway that responds to various extracellular signals and regulates a series of cellular functions involved in metabolism, proliferation, cell survival, growth, angiogenesis, transcription, and protein synthesis. The above process is mediated through serine or threonine phosphorylation of a series of downstream substrates, and the key genes involved are PI3K and AKT (Jafari et al., 2019; Yang et al., 2019). Some chemokines binding to their receptors can activate the PI3K/AKT pathway, which in turn promotes a variety of biological functions and plays a critical part in many cancers. In melanoma and colorectal cancer, abnormally high CXCL5 expression activates PI3K/AKT signaling pathways and promotes PD-L1 expression, thereby creating an immunosuppressive microenvironment (Li et al., 2015). Also, Ma et al. found that CXCL12 derived from fibroblasts significantly enhanced the secretion of CXCL6, and the synergistic effect of both chemokines could regulate colon cancer metastasis via PI3K/AKT/mTOR signaling pathway (Ma et al., 2017).

### Involvement in Tumor Invasion and Metastasis

A number of studies have confirmed the critical function of the chemokine axis in tumor metastasis. It has been reported that the expression of chemokine receptors on cancer cells can determine their sites of metastasis. These metastatic sites produce specific chemokines that advance the migration of moving cancer cells to "pre-metastatic ecological sites", which provides favorable circumstances for the growth of metastatic cells (Murphy 2001; Adekoya and Richardson 2020). A variety of chemokines and chemokine receptors are correlated with cancer cell metastasis, and CXCL12/CXCR4 axis is a key representative system, which participates in the metastasis of various tumor cells (Teicher and Fricker 2010; Daniel et al., 2020). Besides, increased expression of CCR7 was remarkably associated with disease stage, grade, lymph node metastasis and neurovascular infiltration in breast cancer. Therefore, Vahedi et al. suggested that this biomarker could be used as a predictor of tumor metastasis and survival in patients (Vahedi et al., 2018). Acharyya et al. concluded that chemoresistance and metastasis are inextricably linked in cancer. CXCR2 blockers can break the CXCL12/2-S100A8/9 amplification circuit that causes chemoresistance, thus enhancing the chemotherapy effect in breast neoplasms, especially in metastasis (Acharyya et al., 2012). In addition, Cheng et al. devoted a large section to detail the role of chemokines and their receptors in the advancement and metastasis of lung cancer (Cheng et al., 2016). CCL18/PITPNM3 was proved to be associated with the

| Chemokine | Receptors | Tumor | Mechanism | Reference |
|-----------|-----------|-------|-----------|-----------|
| CXCL12    | CXCR4     | Primary breast cancer | CXCR4 ↓, CXCL12 ↓ and the CXCL12 promoter region was hypermethylated | Zhou et al. (2009) |
| CXCL12    | CXCR4     | Breast cancer | DNA methylation | Ramos et al. (2011), Dayer et al. (2018) |
| CXCL13    | CXCR6     | Colorectal cancer | Activated a CXCL13/CXCR5/NFκB/p65/miR-334 positive feedback loop pathway | Zhao et al. (2020) |
| CXCL13    | CXCR6     | Osteosarcoma | Regulated the phospholipase C beta, protein kinase C α, c-Src, and nuclear factor-xB signaling pathways | Liu et al. (2020) |
| CXCL11    | CXCR3     | Head and neck squamous cell carcinomas | Mediates tumor lymphatic cross-talk and inflammation-induced tumor | Kumaravel et al. (2020) |
| CXCL11    | CXCR3     | Liver tumor | Activated ERK1/2 through an autocrine signaling pathway | Zhang et al. (2019) |
| CXCL9     | CXCR3     | Tumor | Reinvigoration of CD8 T cell responses in response to PD-1 blocking tumor treatment | Humbelin and Kamphorst, 2019 |
| CCL2      | CCR2      | Hepatocellular carcinoma | Inhibits the recruitment of inflammatory monocytes, infiltration, and M2-polarisation of tumor-associated macrophages | Li et al. (2017) |
| CXCL1/8   | CXCR2     | Colorectal cancer | Recruited neutrophils to colorectal cancer tumor | Ogawa et al. (2019) |
| CXCL12    | CXCR4     | Epithelial ovarian cancer | Promote the proliferation, migration and invasion | Guo et al. (2013) |
| CXCL12    | CXCR4     | Gastrointestinal malignancies | Activation of G protein signaling kinases such as P13K/mTOR and MEK/ERK | Daniel et al. (2020) |
| CXCL12    | CXCR7     | Gastrointestinal malignancies | Activation of β-arrestin mediated signaling | Daniel et al. (2020) |

*Table 2: Effects on chemokines and their receptors in cancer.*
migration, invasion and EMT processes in hepatocellular carcinoma by mediating the NF-κB signaling pathway (Lin et al., 2016). CCL28, a ligand for CCR3/CCR10, was also related to breast cancer growth and metastatic spread (Yang et al., 2017).

**Involvement in Angiogenesis**

Chemokines and their respective receptors are considered to be key regulators of the tumor vascular system with a dual role in tumor angiogenesis. CXC chemokines are divided into two categories in accordance to the presence of ELR (Glu-Leu-Arg) motifs at the N-terminal end: ELR + chemokines and ELR–chemokines. ELR + CXC chemokines, such as CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8, exert angiogenic effects by activating CXCR1 and CXCR2. In contrast, ELR–CXC chemokines, such as CXCL4, CXCL9, CXCL10, CXCL11, and CXCL14, are considered as angiogenesis inhibitors (Rosso et al., 2014).

Tumor angiogenesis plays a prominent role in the process of tumor advancement. Chemokines can interact directly with specific chemokine receptors on vascular endothelial cells and act as regulators of tumor angiogenesis through endothelial cell signaling pathways, ultimately promoting migration and proliferation as well as endothelial cell survival (Keeley et al., 2011). The *in vivo* and *in vitro* experiments of Chen et al. showed that CXCL5 enhanced the angiogenic ability of colorectal cancer tumors in a CXCR2-dependent manner by a specific mechanism of activating the AKT/NF-κB/FOXO1/VEGF-A pathway. In addition, they found that CXCL5 also increased microvessel density in a subcutaneous xenograft tumor model in nude mice by overexpression treatment of CXCL5 (Chen et al., 2019). CCR6 has also been implicated in CCR6-mediated angiogenesis in colorectal cancer. Zhu et al. proposed that CCR6 promoted the secretion of vascular endothelial growth factor A (VEGF-A) through activation of the AKT/NF-κB pathway (Zhu et al., 2018). In studies of tumor angiogenesis in colorectal cancer, CXCL11 and CXCL12 have been shown to have a reciprocal regulatory role (Rupert et al., 2014). In addition to acting directly on vascular endothelial cells, chemokines can also induce the proliferation of vascular endothelial cells through interacting with VEGF, which in turn promotes angiogenesis (Grunewald et al., 2006). Ping et al. found that CXCL12 could promote upregulation of VEGF expression through PI3K/AKT pathway in gliomas (Skvortsova et al., 2019). Moreover, their experimental results of using the CXCR4 antagonist AMD3100 or knocking out the CXCR4 gene showed that VEGF expression was reduced and tumorigenesis and angiogenesis was inhibited in a nude mouse lotus tumor model (Ping et al., 2011). In addition, CXCL8 and CXCL12-induced upregulation of VEGF expression resulted in the stimulation of angiogenic chemokine production (Kryczek et al., 2005; Martin et al., 2009).

On the other hand, chemokines also have the function of inhibiting tumor angiogenesis and endothelial cell proliferation. For instances, CCL19 could suppress tumor angiogenesis by promoting miR-206 expression dependently on CCR7, and thereby inhibiting the Met/ERK/Elk-1/HIF-1α/VEGF-A pathway. These results were also confirmed in a mouse angiogenesis model, where enhanced CCL19 expression inhibited angiogenesis in colorectal cancer *in vivo* (Xu et al., 2018). CXCL4L1 is a natural non-allelic variant of CXCL4. Struyf et al. proposed that CXCL4L1 was an effective anti-tumor chemokine, which can prevent the progression and metastasis of various tumors by inhibiting angiogenesis (Struyf et al., 2007). Furthermore, it has been postulated that CXCL4L1 exhibited vasopressor and chemotactic activity mediated by CXCR3 (Struyf et al., 2011). The CXCL12/CXCR4 biological axis is also closely related to tumor angiogenesis, and blocking this axis can inhibit tumor angiogenesis either by inhibiting VEGF or directly. Therefore, small molecule antagonists of CXCR4, such as ALX40-4C, AMD3100, and BKT140, have been used in tumor-related treatments (Sun et al., 2013). CXCL9, CXCL10, and CXCL11/CXCR3 are anti-tumor angiogenic factors, and the inhibition of tumor angiogenesis can be achieved via upregulating the expression of CXCL9, CXCL10, and CXCL11 (Billottet et al., 2013). In a retrospective analysis of 294 NSCLC patients taking Anlotinib, Lu et al. found a downregulation of serum CCL2 levels in patients. The results suggested that changes in serum CCL2 levels could be used as a marker to monitor clinical outcomes of patients with refractory advanced NSCLC (Lu et al., 2019). Other tumor angiogenesis-related chemokines and their receptors, such as CCL21/CCR7 and CXCL4, can be used as targets for anti-tumor angiogenesis therapy (Strieter et al., 1995; Somovilla-Crespo et al., 2013). Interestingly, the CC chemokines not only inhibit pathological angiogenesis but also maintain physiological angiogenesis (Ridiandries et al., 2017).

**Involvement in Tumor Microenvironment**

Tumor microenvironment refers to not only the structure, function, and metabolism of tumor tissues, but also the internal environment of tumor cells themselves (Hinshaw and Shevde 2019; Vitale et al., 2019). The internal and external environment in which the tumor cells are located has a significant impact on the occurrence, growth, and metastasis of the tumor. Tumor microenvironment contains a diversity of cells and components, including lymphocytes, tumor-associated macrophages, cancer-associated fibroblasts, growth factors, cytokines, chemokines (Emon et al., 2018), which are of vital clinical significance for tumor prevention and treatment. Among them, chemokines and their receptors have attracted the attention of many researchers.

The interactions of chemokines and chemokine receptors can recruit immune cell subsets into the tumor microenvironment, and these interactions can regulate tumor progression and metastasis (Lee and Cho 2020). Marjorie et al. concluded that plasma CCL4 was positively correlated with inflammatory mediators and was associated with poor patient prognosis. They further suggested that high expression of CCL4 in colon cancer induces infiltration of tumor-associated macrophages (De la Fuente López et al., 2018). Zhang et al. observed that an increase in CCL3/6/8 led to the recruitment of myeloid cells, which restored immunosuppressive and pro-cancer effects. Further studies showed that depletion of regulatory T cells in pancreatic cancer led to differentiation of inflammatory fibroblast subpopulations, which in turn drove infiltration of bone marrow cells via CCR1, thus revealing a potential new therapeutic approach to alleviate immunosuppression in pancreatic cancer.
In addition, CCL2 plays a role in the recruitment of tumor-associated macrophages, which promote tumor phenotype generation as well as tumor cell invasion and angiogenesis (O’Connor and Heikenwalder 2021). The same is true for CCL24/27 (Lim 2021; Martínez-Rodríguez and Monteagudo 2021). CXCL13 and the receptor CXCR5 represent an emerging example of a chemokine signaling axis that demonstrates the ability to regulate tumor growth and progression. In addition, the CXCL13-CXCR5 axis may also indirectly regulate tumor growth by modulating non-cancerous cells in the tumor microenvironment, particularly immune cells (Hussain et al., 2021). The same applies to describe the critical role of the CXCL12-CXCR4 axis and the CCL2-CCR2 axis in the tumor microenvironment (Meng et al., 2018; Kadomoto et al., 2021). Han et al. proposed that blocking the CXCL8-CXCR1/2 axis alone or in combination with other immunotherapies would be a novel immunotherapeutic strategy (Han et al., 2021).

**TABLE 3 | Clinical trials involving chemokine therapy for cancer.**

| Molecule | Cancer Status | Identiﬁer | Reference |
|----------|---------------|------------|-----------|
| CCL2/Carlumab/CNTO 888 | Ovarian and prostate cancer | Phase I | NCT00537368 |
| | | | Sandhu et al. (2013) |
| CCL2/Carlumab/CNTO 888 | Metastatic prostate cancer | Phase II | NCT00992186 |
| | | | Pienta et al. (2013) |
| CCL2/Carlumab + docetaxel/gemcitabine/paclitaxel/carboplatin + IL-7 | Solid tumors | Phase Ib | NCT01204996 |
| | | | Brana et al. (2015) |
| CCL19 + chimeric antigen receptor (CAR)-engineered T cells + FOLFIRINOX | Hepatocellular carcinoma | Phase I | NCT03198546 |
| | | | Pang et al. (2021) |
| CCR2 + FOLFIRINOX | Advanced pancreatic ductal adenocarcinoma | Phase II | NCT01413022 |
| | | | Nywening et al. (2016) |
| CCR2 + Abraxane + Gemcitabine | Metastatic pancreatic ductal adenocarcinoma | Phase Ib/II | NCT02732938 |
| | | | Noel et al. (2020) |
| CCR4/Mogamulizumab + nivolumab | Advanced/Metastatic solid tumors | Phase I | NCT02476123 |
| | | | Doi et al. (2019) |
| CCR4/Mogamulizumab | Peripheral T-cell lymphomas | Phase II | NCT01192984 |
| | | | Ogura et al. (2014) |
| CCR4/Mogamulizumab + Durvalumab/Tremelimumab | Advanced solid tumors | Phase I | NCT02301130 |
| | | | Zamarin et al. (2020) |
| CCR5/Maraviroc | Refractory colorectal cancer | Phase I | NCT01736813 |
| | | | Halama et al. (2016) |
| CXCR4/BL-8040 | Refractory acute myeloid leukemia | Phase II | NCT00512252 |
| | | | Uy et al. (2012) |
| CXCR4/Motixafortide + Pembrolizumab | Pancreatic ductal adenocarcinoma | Phase IIa | NCT02826486 |
| | | | Bockorny et al. (2020) |
| CXCR4/Motixafortide + Pembrolizumab | Metastatic pancreatic cancer | Phase II | NCT02826486 |
| | | | Bockorny et al. (2021) |
| CXCR4/Balixafortide + Eribulin | Metastatic breast cancer | Phase I | NCT01837095 |
| | | | Pernas et al. (2018) |

**FIGURE 2 | Mechanisms of anti-tumor effects of chemokines and its receptors.**
To date, the main means of treatment for tumors are still surgical treatment, radiation therapy, chemotherapy, and targeted therapy. Surgical treatment is mainly used for diagnosis and radical treatment, which can effectively relieve symptoms and improve survival. In recent years, with the improvement of radiotherapy equipment and the development of computer science, radiotherapy has been more and more widely used in clinical practice and has become an important means of treatment for comprehensive tumors. In addition, with the occurrence of new chemotherapeutic drugs, chemotherapy has acquired therapeutic importance. Although chemotherapy has been used for the treatment of hematologic malignancies, it still needs to be combined with other treatments to improve the efficacy. Meanwhile, targeted therapy has gradually become vital for tumor treatment due to the development of genetic testing technology and small molecule targeted drugs. Targeted therapy enables selective, targeted, patient-friendly, and safer treatment to control tumor, thereby reducing the damage to normal tissues around the tumor. Therefore, it becomes more and more prominent in tumor treatment by virtue of its specificity and less toxicity.

Currently, chemokines and their receptors exhibit positive impacts in cancer biology, such as involvement in angiogenesis, metastasis, proliferation and invasion of cancer cells. Chemokines are also considered to be key influencers on disease progression and have a great effect on patients' treatment and prognosis. In recent years, chemokines have been used as important therapeutic targets for cancer. Mogamulizumab (an anti-CCR4 antibody) and Plerixafor/AMD3100 (a CXCR4 antagonist) have been approved for the treatment of hematologic malignancies and being in clinical trials (Bule et al., 2021). In addition, Wsotermann et al. used CCL19-conjugated DNA vaccine for tumor control and showed that the combination of the two significantly inhibited tumor growth and prolonged the antitumor effect of the vaccine (Wsotermann et al., 2007). Subsequent studies have also confirmed that CCL19 can be used as an adjuvant for immunization with intraderal gene guns in a Her2/neu mouse tumor model, with enhanced vaccine efficacy (Nguyen-Hoai et al., 2012). Not coincidentally, the combination of CCL19/21 with CCL4 can also be used as an adjuvant for DNA vaccination in Her2/neu mouse tumor models (Nguyen-Hoai et al., 2016). In a recent clinical trial, Peng et al. found that the incorporation of CCL19 into chimeric antigen receptor (CAR)-engineered T cells dramatically improved the antitumor activity against human solid tumors, which has been in phase I clinical trial (NCT03198546) (Pang et al., 2021). CCR2 in combination with FOLFIRINOX for advanced pancreatic ductal adenocarcinoma is in clinical phase II (NCT01413022) (Nywening et al., 2016). Additionally, CCR2 combined with Abraxane and Gemcitabine for metastatic pancreatic ductal adenocarcinoma is in phase Ib/II (NCT02732938) clinical trial (Noel et al., 2020). Other chemokines and receptors, such as CCL2 (Sandhu et al., 2013), CCR5 (Doi et al., 2019), and CXCR4 (Ghobrial et al., 2020), have also been used in combination with other drugs in a variety of cancers. More clinical trials involving chemokine therapy is listed in Table 3.

CONCLUSION AND PROSPECT

Cancer is a life-threatening disease that imposes an economic burden on society. Due to its complexity and treatment resistance, diagnosing and curing cancer is a huge challenge. Despite recent advances in therapeutic strategies such as immunotherapy and targeted therapy, survival rates of cancer patients have not been reduced evidently. Chemokines are a large class of cytokines that coordinate the tropism of immune cell transport. They also participate in numerous cancer processes and serve as a critical part in the migration patterns of immune cells into tumors. The mechanisms of anti-tumor effects of chemokines and its receptors were briefly summarized in Figure 2.

The relationship between chemokines and/or chemokine receptors and tumors is complex and multifaceted, and has become a hot and difficult area in current tumor biology research. With the development of molecular biology, molecular immunology and related technologies, the role of chemokines/chemokine receptors system in tumor development and the related mechanisms have been gradually discovered. As a result, targeting these molecules may provide new strategies and means to targeted therapy of tumor. Through more in-depth research on tumor pathogenesis, more effective indicators for early diagnosis and determination of recurrence can be found, which will effectively reduce the morbidity and recurrence rate of cancer patients. A number of studies have suggested that chemokines can be involved in tumor development through a network of a variety of mechanisms. Also, chemokines are expected to become important indicators for tumor screening, diagnosis and monitoring in the future, because of the advantages of easy detection, low cost, and no surgery-related risks. Study of tumor-related chemokines has gradually turned into a research hotspot, although the specific biological properties and mechanism of action are still not fully elucidated. At present, some chemokines have been used as tumor diagnostic markers in clinical practice, and some chemokine-targeting drugs have entered various phases of clinical trial. Unfortunately, single-targeted chemokine therapeutic drugs have mostly ended up in failure. The new pathway of multicomplexer-based therapies will better help researchers discover new drugs with high effectiveness without negative impacts.

In summary, chemokines and their receptors are expected to become targets for new anti-tumor drugs and may provide a new approach to cancer therapy. As the mechanisms of interaction between chemokines and/or their receptors and cancer continue to be studied, chemokines and their receptors may also become predictors of cancer, which may then provide new strategies for targeted therapy and prevention of cancer.

AUTHOR CONTRIBUTIONS

Conceptualization HC, HS and JZ; writing—original draft preparation, JX, JL and QG; writing—review and editing, ES,
VM, VP and ET; funding acquisition, HC, HS and JZ. All authors have read and agreed to the published version of the manuscript.

**FUNDING**

This work is supported by National Key R&D Project of China (2021YFF0202000), Fund of Guangdong Education Department (2021DZX2006), the Health and Medical Research Fund in Hong Kong (16170251), the Innovation and Technology Fund in Hong Kong (PRP/036/20FX; MHP/023/20).

**ACKNOWLEDGMENTS**

We thank all the participants for their help.

**REFERENCES**

Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., et al. (2012). A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis. Cell 150 (1), 165–178. doi:10.1016/j.cell.2012.04.042

Adekoya, T. O., and Richardson, R. M. (2020). Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis. Int. J. Mol. Sci. 21 (12). doi:10.3390/ijms21124449

Anderson, N. M., and Simon, M. C. (2020). The Tumor Microenvironment. Frontiers in Pharmacology | www.frontiersin.org June 2022 | Volume 13 | Article 920779

Adekoya, T. O., and Richardson, R. M. (2020). Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis. Int. J. Mol. Sci. 21 (12). doi:10.3390/ijms21124449

Bockorny, B., Semenisty, V., Macarulla, T., Borazanci, E., Wolpin, B. M., Stemmer, Bosisio, D., Salvi, V., Gagliostro, V., and Sozzani, S. (2014). Angiogenic and Borroni, E. M., Savino, B., Bonecchi, R., and Locati, M. (2018). Chemokines Sound

Bestor, T. H., and Verdine, G. L. (1994). DNA Methyltransferases.

Chen, C., Xu, Z. Q., Zong, Y. P., Ou, B. C., Shen, X. H., Feng, H., et al. (2019). CXCR4 as a Prognostic Marker in Human Breast Cancer. J. Cancer 10 (11), 2694–2704. doi:10.7150/jca.27716

Cheng, S., Han, L., Guo, J., Yang, Q., Zhou, J., and Yang, X. (2014). The Essential Roles of CCR7 in Epithelial-To-Mesenchymal Transition Induced by Hypoxia in Epithelial Ovarian Carcinomas. Tumour Biol. 35 (12), 12293–12298. doi:10.1007/s13277-014-2540-6

Cheng, Z. H., Shi, X. Y., Yuan, M., Xiong, D., Zheng, J. H., and Zhang, Z. Y. (2016). Chemokines and Their Receptors in Lung Cancer Progression and Metastasis. J. Beijing Univ. Med. Sci. 37 (5), 342–351. doi:10.1631/jzus.B1500258

Chow, M. T., and Luster, A. D. (2014). Chemokines in Cancer. Cancer Immunol. Res. 2 (12), 1125–1131. doi:10.1158/2326-6066.CIR-14-0160

Comerford, I., Harata-Lee, Y., Bunting, M. D., Gregor, C., Kara, E. E., and McColl, S. R. (2013). A Myriad of Functions and Complex Regulation of the CCR7/ CCL19/CCL21 Chemokine axis in the Adaptive Immune System. Cytokine Growth Factor Rev. 24 (3), 269–283. doi:10.1016/j.cytogfr.2013.03.001

Daniel, S. K., Seo, Y. D., and Pillarsetty, V. G. (2020). The CXCL12-CXcr4/cxcr7 axis as a Mechanism of Immune Resistance in Gastrointestinal Malignancies. Semin. Cancer Biol. 65, 176–188. doi:10.1016/j.semcancer.2019.12.007

Dawson, M. A., and Kouzarides, T. (2012). Cancer Epigenetics: from Mechanism to Therapy, Cell 150 (1), 12–27. doi:10.1016/j.cell.2012.06.013

Dayer, R., Babashah, S., Jamshidi, S., and Sadeghizadeh, M. (2018). Upregulation of CXC Chemokine Receptor 4-CXCL Chemokine Ligand 12 axis Invasive Breast Carcinoma: A Potent Biomarker Predicting Lymph Node Metastasis. J. Cancer Res. Ther. 14 (2), 345–350. doi:10.4103/0973-1482.177221

De la Fuente López, M., Landskron, G., Parada, D., Dubois-Camacho, K., Simian, D., Martinez, M., et al. (2018). The Relationship between Chemokines CCL2, CCL3, and CCL4 with the Tumor Microenvironment and Tumor-Associated Macrophage Markers in Colorectal Cancer. Tumour Biol. 40 (11), 1010428318810059. doi:10.1177/1042831818810059

DeBerardinis, R. J. (2020). Tumor Microenvironment, Metabolism, and Immunotherapy. N. Engl. J. Med. 382 (9), 869–871. doi:10.1056/NEJMcir1914890

Doi, T., Muro, K., Ishii, H., Kato, T., Tsuchima, T., Takenoyama, M., et al. (2019). A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors. Clin. Cancer Res. 25 (22), 6614–6622. doi:10.1158/1078-0432.CCR-19-1090

Emon, B., Bauer, J., Jain, Y., Jung, B., and Saif, T. (2018). Biophysics of Tumor Microenvironment and Cancer Metastasis - A Mini Review. Comput. Struct. Biotechnol. J. 16, 279–287. doi:10.1515/csbj-2018-00703

Fernandez, E. J., and Lolis, E. (2002). Structure, Function, and Inhibition of Chemokines. Annu. Rev. Pharmacol. Toxicol. 42, 469–499. doi:10.1146/annurev.pharmtox.42.091901.115838

Forster, R., Davalos-Misslitz, A. C., and Rot, A. (2008). CCR7 and its Ligands: Balancing Immunity and Tolerance. Nat. Rev. Immunol. 8 (5), 362–371. doi:10.1038/nri2297

Ghobrial, I. M., Liu, C. J., Redd, R. A., Perez, R. P., Baz, R., Zavidii, O., et al. (2020). A Phase Ib/II Trial of the First-In-Class Anti-CXCR4 Antibody Ubolomubab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clin. Cancer Res. 26 (2), 344–353. doi:10.1158/1078-0432.CCR-19-0647

Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Jung, S., et al. (2006). VEGF-induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells. Cell 124 (1), 175–189. doi:10.1016/j.cell.2005.10.036

Guo, Q., Wu, X. H., Lü, Y. P., Yang, B., Xu, F., and Zhang, S. J. (2013). Relationship between Chemokine axis CXCL12-CXCR4 and Epithelial Ovarian Cancer. Zhonghua yi xue za zhi 93 (21), 1677–1680.
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., et al. (2016). Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CR5 Therapy in Cancer Patients. Cancer Cell 29 (4), 587–601. doi:10.1016/j.ccell.2016.03.005

Huang, L., Ma, B., Ma, J., and Wang, F. (2017). Fractalkine/CX3CR1 axis. Frontiers in Pharmacology | www.frontiersin.org June 2022 | Volume 13 | Article 920779

Hughes, C. E., and Nibbs, R. J. B. (2018). A Guide to Chemokines and Their Receptors. FEBS J. 285 (26), 3971–3991. doi:10.1111/febs.14466

Humblin, E., and Kamphorst, A. O. (2019). CXCR3-CXCL9: It’s All in the Tumor. Immunology 50 (6), 1347–1349. doi:10.1111/immu.2019.05.015

Hussain, M., Liu, J., Wang, G. Z., and Zhou, G. B. (2021). CXCL13 Signaling in the Tumor Microenvironment. Adv. Exp. Med. Biol. 13993003.01562-2018

Jafari, M., Ghadami, E., Dadkhah, T., and Akhavan-Niaki, H. (2019). PI3k/AKT Signaling Pathway. Frontiers in Pharmacology | www.frontiersin.org June 2022 | Volume 13 | Article 920779

Kryczek, I., Lange, A., Mottram, P., Alvarez, X., Chen, Q., Guo, T. K., Li, Y., et al. (2017). Fibroblast-Derived CCL2 Increases Migration, Invasion, and EMT through the NF-kappaB Pathway in Endothelial Cells by Activating NFkappaB through the CBM (Carma3/Beil0/Malt1) Complex. J. Biol. Chem. 285 (10), 6038–6042. doi:10.1074/jbc.C80027200

Kumar, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., et al. (2021). IL-7 and IL-15 Increase the Motility of Cancer Cells through the Neutrophil Chemokines CXCL1 and CXCL2. Frontiers in Immunology | www.frontiersin.org June 2022 | Volume 13 | Article 920780

Ma, J., Sun, X., Wang, Y., Chen, B., Qian, L., and Wang, Y. (2019). Fibroblast-Derived CCL12 Regulates PTEN Expression and Is Associated with the Proliferation and Invasion of Colon Cancer Cells via PI3K/Akt Signaling. Cell Commun. Signal 17 (1), 119. doi:10.1186/s12951-019-0432-5

Martin, D., Galisteo, R., and Gutkind, J. S. (2009). CCL5/L15 Stimulates Vascular Endothelial Growth Factor (VEGF) Expression and the Autocrine Activation of VEGFR2 in Endothelial Cells by Activating NKappab through the CBM (Carma3/Beil0/Malt1) Complex. J. Biol. Chem. 284 (10), 6038–6042. doi:10.1074/jbc.C80027200

Moore, L. D., Le, T., and Fan, G. (2013). DNA Methylation and its Basic Function. Neuropsychopharmacology 38 (1), 23–38. doi:10.1038/npp.2012.112

Müller, A., Homey, B., Soto, H., Catron, D., Buchanan, M. E., et al. (2001). Involvement of Chemokine Receptors in Breast Cancer Metastasis. Nature 410 (6824), 50–56. doi:10.1038/35065016

Murphy, P. M. (2001). Chemokines and the Molecular Basis of Cancer Metastasis. N. Engl. J. Med. 345 (11), 833–835. doi:10.1056/Nejm200109133451113

Nagarsheth, N., Wicha, M. S., and Zou, W. (2017). Chemokines in the Cancer Tumor Microenvironment and Their Relevance in Cancer Immunotherapy. Nat. Rev. Immunol. 17 (9), 559–572. doi:10.1038/nri.2017.49

Nguyen-Hoi, T., Hohn, O., Vu, M. D., Baldenhofer, G., Sayed Ahmed, M. S., Dörken, B., et al. (2012). CCL19 as an Adjuvant for Intradermal Gene Gun Immunization in a Her2/neu Mouse Tumor Model: Improved Vaccine Efficacy and a Role for B Cells as APC. Cancer Gene Ther. 19 (12), 880–887. doi:10.1038/cgt.2012.78

Nguyen-Hoi, T., Pham-Duc, M., Gries, M., Dörken, B., Pezzutto, A., and Westermann, J. (2016). CCL4 as an Adjuvant for DNA Vaccination in a Her2/neu Mouse Tumor Model. Cancer Gene Ther. 23 (6), 162–167. doi:10.1038/cgt.2016.9

Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., et al. (2020). Phase 1b Study of a Small Molecule Antagonist of Human Chemokine (C-C Motif) Receptor 2 (PF-04136309) in Combination with Nab-Paclitaxel/gemcitabine in First-Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma. Invest. New Drugs 38 (3), 800–811. doi:10.1007/s10637-019-00830-3

Nywenning, T. M., Wang-Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Csizmabony, B. M., et al. (2016). Targeting Tumour-Associated Macrophages with CCR2 Inhibition in Combination with FOLFIRINOX in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer: a Single-Centre, Open-Label, Dose-Finding, Non-randomised, Phase 1b Trial. Lancet Oncol. 17 (5), 651–662. doi:10.1016/S1470-224X(16)00078-4

O’Connor, T., and Heikenwalder, M. (2021). CCL2 in the Tumor Microenvironment. Adv. Exp. Med. Biol. 1302, 1–14. doi:10.1007/978-3-030-62658-7_1

Ogawa, R., Yamamoto, T., Hirai, H., Hanada, K., Kiyasu, Y., Nishikawa, G., et al. (2019). Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL18/CXCR2 Axis. Clin. Cancer Res. 25 (9), 2887–2899. doi:10.1158/1078-0432.CCR-18-3684

Ogura, M., Ishida, T., Hatake, K., Taniwaki, M., Ando, K., Tobinai, K., et al. (2014). Down-Regulating Caspase-3 =VEGFR2 in Endothelial Cells by Activating NFkappaB through the CBM (Carma3/Beil0/Malt1) Complex. J. Biol. Chem. 289 (23), 19057–19069. doi:10.1074/jbc.M114.561232

Pang, X., Li, K., Wei, L., Huang, Y., Su, M., Wang, L., et al. (2018). IL-8 Inhibits the Apoptosis of MCF-7 Human Breast Cancer Cells by Up-Regulating Bel-2 and Down-Regulating Caspase-3 – Xi Bu Yu Fen Zhi Xian Yi Xue Za Zhi. 2015;11(3):307–311.

Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., et al. (2021). IL-7 and CCL19-Secreting CAR-T Cell Therapy for Tumors with Positive Glypican-3 or Mesothelin. J. Hematol. Oncol. 14 (1), 118. doi:10.1186/s13045-021-01128-9
Pienta, K. J., Machiels, J. P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., et al. (2015). Frontiers in Pharmacology | www.frontiersin.org June 2022 | Volume 13 | Article 920779

Song, E. Y., Shurin, M. R., Tourkova, I. L., Gutkin, D. W., and Shurin, G. V. (2010). J. Hematol. Oncol. 3 (1), 730–740. doi:10.1186/1756-8722-3-730

Struyf, S., Salogini, L., Burdick, M. D., Vanderspellen, J., Gouwy, M., Noppen, S., et al. (2011). Angiostatic and Chemotactic Activities of the CXC Chemokine CXCL4L1 (Platelet Factor-4 Variant) Are Mediated by CXCR3. Blood 117 (2), 480–488. doi:10.1182/blood-2009-11-253591

Sun, X., Charbonneau, C., Wei, L., Yang, W., Chen, Q., and Terek, R. M. (2013). CXCR4-targeted Therapy Inhibits VEGF Expression and Chondrosarcoma Angiogenesis and Metastasis. Mol. Cancer Ther. 12 (7), 1163–1170. doi:10.1158/1535-7163.MCT-12-1092

Tajima, S., Suetake, I., Takeshita, K., Nakagawa, A., and Kimura, H. (2016). Domain Structure of the Drmt1, Drmt3a, and Drmt3b DNA Methyltransferases. Adv. Exp. Med. Biol. 945, 63–86. doi:10.1007/978-3-319-43624-1_4

Teicher, B. A., and Fricker, S. P. (2010). CXCL12 (SDF-1/CXCR4 Pathway in Cancer. Clin. Cancer Res. 16 (11), 2927–2931. doi:10.1158/1078-0432.CCR-09-3239

Tessema, M., Klinge, D. M., Yingling, C. M., Do, K., Van Neste, L., and Belinsky, S. A. (2010). Re-expression of CXCL14, a Common Target for Epigenetic Silencing in Lung Cancer, Induces Tumor Necrosis. Oncogene 29 (37), 5159–5170. doi:10.1038/onc.2010.255

Thelen, M., and Stein, J. V. (2008). How Chemokines Invite Leukocytes to Dance. Nat. Immunol. 9 (9), 953–959. doi:10.1038/ni2070

Toh, T. B., Lim, J. J., and Chow, E. K. (2017). Epigenetics in Cancer Stem Cells. Mol. Cancer 16 (1), 29. doi:10.1186/s12943-017-0596-9

Uy, G. L., Retting, M. P., Motabi, I. H., McFarland, K., Trinkaus, K. M., Hladnik, L. M., et al. (2012). A Phase 1/2 Study of Chemosensitization with the CXCR4 Antagonist Plaxirza in Relapsed or Refractory Acute Myeloid Leukemia. Blood 119 (17), 3917–3924. doi:10.1182/blood-2011-10-383406

Vahedi, L., Ghasemi, M., Yazdani, J., Ranbar, S., Nouri, B., Alizadeh, A., et al. (2018). Investigation of CCR7 Marker Expression Using Immunohistochemical Method and its Association with Clinicopathologic Properties in Patients with Breast Cancer. Int. J. Hematol. Oncol. Stem Cell Res. 12 (2), 103–110.

van der Vorst, E. P., Döring, Y., and Weber, C. (2015). Epithelial-Mesenchymal Transition and Suppressing Apoptosis through AKT Pathway. Cancer Med. 6 (5), 1062–1071. doi:10.1002/cam4.1039

Xu, Z., Zhu, C., Chen, C., Zong, Y., Feng, H., Liu, D., et al. (2018). CCL19 Suppresses Angiogenesis through Promoting miR-206 and Inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A Pathway in Colorectal Cancer. Cell Death Dis. 9 (10), 974. doi:10.1038/s41419-018-1010-2

Yang, X. L., Liu, K. Y., Shi, H. M., and Ou, Z. L. (2017). CCL28 Promotes Melanoma and Lung Carcinoma Growth and Metastasis by Preventing ERK/Elk-1/HIF-1α/VEGF-A Pathway in Colorectal Cancer. Cell Death Dis. 9 (10), 974. doi:10.1038/s41419-018-1010-2

Yang, X. L., Liu, K. Y., Shi, H. M., and Ou, Z. L. (2017). CCL28 Promotes Melanoma and Lung Carcinoma Growth and Metastasis by Preventing ERK/Elk-1/HIF-1α/VEGF-A Pathway in Colorectal Cancer. Cell Death Dis. 9 (10), 974. doi:10.1038/s41419-018-1010-2

Xu, Z., Zhu, C., Chen, C., Zong, Y., Feng, H., Liu, D., et al. (2018). CCL19 Suppresses Angiogenesis through Promoting miR-206 and Inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A Pathway in Colorectal Cancer. Cell Death Dis. 9 (10), 974. doi:10.1038/s41419-018-1010-2

Yu, G. L., Retting, M. P., Motabi, I. H., McFarland, K., Trinkaus, K. M., Hladnik, L. M., et al. (2012). A Phase 1/2 Study of Chemosensitization with the CXCR4 Antagonist Plaxirza in Relapsed or Refractory Acute Myeloid Leukemia. Blood 119 (17), 3917–3924. doi:10.1182/blood-2011-10-383406

Vahedi, L., Ghasemi, M., Yazdani, J., Ranbar, S., Nouri, B., Alizadeh, A., et al. (2018). Investigation of CCR7 Marker Expression Using Immunohistochemical Method and its Association with Clinicopathologic Properties in Patients with Breast Cancer. Int. J. Hematol. Oncol. Stem Cell Res. 12 (2), 103–110.

van der Vorst, E. P., Döring, Y., and Weber, C. (2015). Epithelial-Mesenchymal Transition and Suppressing Apoptosis through AKT Pathway. Cancer Med. 6 (5), 1062–1071. doi:10.1002/cam4.1039

Xu, Z., Zhu, C., Chen, C., Zong, Y., Feng, H., Liu, D., et al. (2018). CCL19 Suppresses Angiogenesis through Promoting miR-206 and Inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A Pathway in Colorectal Cancer. Cell Death Dis. 9 (10), 974. doi:10.1038/s41419-018-1010-2

Yang, X. L., Liu, K. Y., Shi, H. M., and Ou, Z. L. (2017). CCL28 Promotes Breast Cancer Growth and Metastasis through MAPK-Mediated Cellular Anti-apoptosis and Pro-metastasis. Oncol. Rep. 38 (3), 1393–1401. doi:10.3892/or.2017.5798

Yang, Q., Jiang, W., and Hou, P. (2019). Emerging Role of PI3K/AKT in Tumor-Related Epigenetic Regulation. Semin. Cancer Biol. 59, 112–124. doi:10.1016/j.semcancer.2019.04.001

Yang, F., Zhang, S., Meng, Q., Zhou, F., Pan, B., Liu, F., et al. (2021). CXCR1 Correlates to Poor Outcomes of EGFR-TKI against Advanced Non-small Cell Lung Cancer by Activating Chemokine and JAK/STAT Pathway. Palm. Pharmacol. Ther. 67, 102001. doi:10.1016/j.pupt.2021.102001

Zanarin, D., Hamid, O., Nayak-Kapoor, A., Sahbehjan, S., Sinol, M., Collaku, A., et al. (2020). Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clin. Cancer Res. 26 (17), 4531–4541. doi:10.1158/1078-0432.CCR-20-0328

Zhang, X., Fu, R., Yu, J., and Wu, X. (2014). DNA Methylation: where Genetics Meets Epigenetics. Curr. Pharm. Des. 20 (11), 1625–1631. doi:10.2174/138161211319990546
Zhang, L., Xiao, X., An, H., Wang, J., Ma, Y., and Qian, Y. H. (2017). Inhibition of CCR7 Promotes NF-κB-dependent Apoptosis and Suppresses Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer. Oncol. Rep. 37 (3), 2913–2919. doi:10.3892/or.2017.5524

Zhang, Y., Zhao, W., Li, S., Lv, M., Yang, X., Li, M., et al. (2019). CXCL11 Promotes Self-Renewal and Tumorigenicity of α2δ1+ Liver Tumor-Initiating Cells through CXCR3/ERK1/2 Signaling. Cancer Lett. 449, 163–171. doi:10.1016/j.canlet.2019.02.016

Zhang, Y., Lazarus, J., Steele, N. G., Yan, W., Lee, H. J., Nwosu, Z. C., et al. (2020). Regulatory T-Cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis. Cancer Discov. 10 (3), 422–439. doi:10.1158/2159-8290.CD-19-0958

Zhao, S., Mi, Y., Guan, B., Zheng, B., Wei, P., Gu, Y., et al. (2020). Tumor-derived Exosomal miR-934 Induces Macrophage M2 Polarization to Promote Liver Metastasis of Colorectal Cancer. J. Hematol. Oncol. 13 (1), 156. doi:10.1186/s13045-020-00991-2

Zheng, J., Wang, J., Sun, X., Hao, M., Ding, T., Xiong, D., et al. (2013). HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification. Clin. Cancer Res. 19 (6), 1400–1410. doi:10.1158/1078-0432.CCR-12-2888

Zheng, Y., Wang, Z., Wei, S., Liu, Z., and Chen, G. (2021). Epigenetic Silencing of Chemokine CCL2 Represses Macrophage Infiltration to Potentiate Tumor Development in Small Cell Lung Cancer. Cancer Lett. 499, 148–163. doi:10.1016/j.canlet.2020.11.034

Zhi, Y., Chen, J., Zhang, S., Chang, X., Ma, J., and Dai, D. (2012). Down-regulation of CXCL12 by DNA Hypermethylation and its Involvement in Gastric Cancer Metastatic Progression. Dig. Dis. Sci. 57 (3), 650–659. doi:10.1007/s10620-011-1922-5

Zhou, W., Jiang, Z., Liu, N., Xu, F., Wen, P., Liu, Y., et al. (2009). Down-regulation of CXCL12 mRNA Expression by Promoter Hypermethylation and its Association with Metastatic Progression in Human Breast Carcinomas. J. Cancer Res. Clin. Oncol. 135 (1), 91–102. doi:10.1007/s00432-008-0435-x

Zhou, R., Sun, J., He, C., Huang, C., and Yu, H. (2020). CCL19 Suppresses Gastric Cancer Cell Proliferation, Migration, and Invasion through the CCL19/CCR7/AIM2 Pathway. Hum. Cell 33 (4), 1120–1132. doi:10.1007/s13577-020-00375-1

Zhu, Z., Zhang, X., Guo, H., Fu, L., Pan, G., and Sun, Y. (2015). CXCL13-CXCR5 axis Promotes the Growth and Invasion of Colon Cancer Cells via PI3K/AKT Pathway. Mol. Cell Biochem. 400 (1-2), 287–295. doi:10.1007/s11010-014-2285-y

Zhu, C. C., Chen, C., Xu, Z. Q., Zhao, J. K., Ou, B. C., Sun, J., et al. (2018). CCR6 Promotes Tumor Angiogenesis via the AKT/VEGF Pathway in Colorectal Cancer. Biochim. Biophys. Acta Mol. Basis Dis. 1864 (2), 387–397. doi:10.1016/j.bbadis.2017.10.033

Zlotnik, A., and Yoshie, O. (2012). The Chemokine Superfamily Revisited. Immunity 36 (5), 705–716. doi:10.1016/j.immuni.2012.05.008

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xu, Li, Chen, Shestakova, Misyurin, Pokrovsky, Tchevkina, Chen, Song and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.